{'fraction_non_alphanumeric': 0.038461538461538464, 'fraction_numerical': 0.017241379310344827, 'mean_word_length': 6.05607476635514, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Subcutaneous administration of somatostatin analogs as a major factor in the enhancement of the duration of action.

Somatostatin and Des(Ala1Gly2)desaminol[Cys3]descarboxy-]Cys14[-]D-Trp8[dicarba3,14-somatostatin (Ia) are more potent inhibitors of glucagon, insulin and growth hormone release than the L-Trp8 analog (Ib). However when infused intravenously, these three compounds are equipotent but short-acting inhibitors of pentagastrin evoked gastric secretion in the dog. The duration of inhibition of equieffective antisecretory doses is significantly increased following subcutaneous administration 30 min prior to a food stimulus. The longest duration of antisecretory action is seen with the D-Trp8 analog (Ia) after subcutaneous administration.